Association of Gene Mutations with Response to Arsenic-Containing Compound Qinghuang Powder () in Patients with Myelodysplastic Syndromes

Chin J Integr Med. 2019 Jun;25(6):409-415. doi: 10.1007/s11655-018-2977-3. Epub 2018 Apr 4.

Abstract

Objectives: To investigate the relationship between gene mutations and response to Compound Qinghuang Powder (, CQHP) in patients with myelodysplastic syndrome (MDS).

Methods: Forty-three MDS patients were genotyped by ultra-deep targeted sequencing and the clinical data of patients were collected and the relationship between them was analyzed.

Results: Up to 41.86% of patients harbored genet mutations, in most cases with more than one mutation. The most common mutations were in SF3B1, U2AF1, ASXL1, and DNMT3A. After treatment with CQHP, about 88.00% of patients no longer required blood transfusion, or needed half of prior transfusions.

Conclusions: CQHP is an effective treatment for patients with MDS, especially those with gene mutations in SF3B1, DNMT3A, U2AF1, and/or ASXL1.

Keywords: arsenic; myelodysplastic syndromes; next-generation sequencing; realgar.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Arsenic / therapeutic use*
  • Arsenicals / therapeutic use*
  • Blood Transfusion
  • Drugs, Chinese Herbal / therapeutic use*
  • Female
  • Genetic Association Studies*
  • Humans
  • Karyotype
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics*
  • Treatment Outcome

Substances

  • Arsenicals
  • Drugs, Chinese Herbal
  • qinghuang
  • Arsenic